Company intelligence / Profile preview

Hyperthermia Cancer Institute

Santa Monica, California, United States

Ownership: Private
Development stage: Other

Overview

Hyperthermia Cancer Institute (HCI) offers a commercial hyperthermia treatment that uses FDA-approved ultrasound technology as an adjunct to standard cancer therapies. Clinical outcomes are described anecdotally as tumor reduction and improved complete response rates when combined with chemotherapy or radiation, with reportedly low side effect rates.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on Hyperthermia Cancer Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyperthermia Cancer Institute.

Explore the full profile